:
Coronavirus diseases (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), which is a
positive single-stranded RNA virus having a large genome ~30 kb. SARS-CoV-2 is zoonotic and highly contagious, causing severe
pneumonia-like symptoms. The efficacy of the different potential drug and drug candidates against COVID-19 has been investigated which
are under various stages of clinical trials. The drugs effective against SARS, and Middle east respiratory syndrome (MERS), have been
proposed to have a high potential for the treatment of COVID-19. Here, we selected plant-based materials implicated in the prevention and
therapy of COVID-19. The vaccine has shown impressive results in producing antibodies against SARS-CoV2 and has been evaluated for
safety, tolerance, and preliminary immunogenicity. Similarly, DNA/RNA-based therapy shown high clinical significance. The plant produces
secondary metabolites in response to viral infection to protect them. Many nanomaterials produced by carbohydrates and lipids been exploited
for their in-vitro and in-vivo delivery of antiviral therapeutics. Different classes of secondary metabolites have a different mechanism to
counter virus attacks. While some natural medicines in the form of vitamins, minerals, herbs, and other nutrients help to enhance immunity,
such measures should not replace social distancing, quarantining special care to protect from COVID-19. The standards of reporting were in
accordance with the PRISMA guidelines.